Head to Head

KNSA vs OGN: which is the better buy in 2026?

Kiniksa Pharmaceuticals International, plc

NASDAQ:KNSA

90/100 Compass

True NorthAccumulate$4.6B

A one-drug company quietly becoming a two-drug franchise, with the second drug potentially bigger than the first.

Full KNSA analysis

Organon & Co.

NYSE:OGN

90/100 Compass

True NorthAccumulate$3.5B

A 3.6x forward P/E spinoff drowning in debt that just happens to throw off half a billion in cash, women's health is the call option.

Full OGN analysis

Factor by factor

FactorKNSAOGN

Revenue Growth9835

Profitability5642

Valuation4875

Momentum8990

Theme Purity5859

Moat5045

Catalysts6365

Market Position4848

Get head-to-heads like this, free

Join the Alexandria e-letter for Compass verdicts, earnings intelligence, and the contrarian calls the crowd misses. Twice a week, no noise.

Free forever. Unsubscribe anytime. We never share your email.

Frequently asked questions

Is KNSA or OGN the better buy in 2026?

KNSA and OGN are neck and neck at 90/100 on the Compass right now. The better fit depends on which factors matter most to you.

How does Alexandria compare KNSA and OGN?

Each company is scored 1-100 on eight factors: revenue growth, profitability, valuation, momentum, theme purity, moat, catalysts, and market position. The Compass Score is the composite, and the comparison below shows where each name wins factor by factor.

Compass Scores are proprietary editorial research from publicly available data, not investment advice or a recommendation regarding any security. Rankings update weekly.